Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · INOVIO PHARMACEUTICALS, INC. (INO)

Inovio estimates $48.4 million cash and short-term investments at September 30, 2026

Neutral Impact 3 of 5 earnings Written later

Inovio Pharmaceuticals disclosed a preliminary, unaudited estimate that its cash, cash equivalents and short-term investments were about $48.4 million as of September 30, 2026. The company says the figure is not a full quarterly result, is subject to closing procedures, and has not been audited or reviewed by Ernst & Young LLP, and actual results may differ materially.

Key points

  • Preliminary cash, cash equivalents and short-term investments: approximately $48.4 million as of September 30, 2026
  • Figure is based on unaudited information and management estimates for the quarter ended September 30, 2026
  • Ernst & Young LLP has not audited, reviewed or provided assurance on the preliminary data
  • Filing was signed by CFO Peter Kies on November 5, 2026

The filing

CompanyINOVIO PHARMACEUTICALS, INC. (INO)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:13 PM ET
Accession number0001193125-26-449853

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.